Loading…
Employees: 174
Size Rigel Pharmaceuticals (RIGL) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $741M, the 2443rd largest of 3,117 United States companies the cockpit tracks. Shares closed at $39.65 on 6 Nov 2026.
Performance Over six months the shares gained 52.3%, against -18.1% for the median peer and -1.1% for the United States market (cap-weighted) — 2nd highest of 20 in its peer set.
Growth Revenue grew 3.3% over the last twelve months (peer median +5.9%); the operating margin is 31.4% (peer median 11.0%).
Valuation It trades at 11.9× forward earnings against a peer median of 17.8× (5th cheapest of 12).
Price implies For today's price to make sense, revenue must grow about -1% a year for seven years (Req g). Recent delivered growth is +22%, so the hurdle is -23 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 7.7 points above its cost of capital (10.9% WACC).
Short interest Short interest is 14.6% of the free float (15 Oct 2026).
Next results Next results expected around 9 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $277M | $294M | $179M | $117M | $120M |
| Revenue growth | — | +64% | +53% | -3% | — |
| Gross profit | $253M | $275M | $161M | $110M | $118M |
| EBITDA | $89.7M | $128M | $26.4M | -$19.3M | -$53.2M |
| Net income | $322M | $367M | $17.5M | -$25.1M | -$58.6M |
| Free cash flow | $79.4M | $75.7M | $31.4M | -$5.74M | -$74.2M |
| Capital expenditure | $70.3M | $0 | $396,000 | $15.0M | $450,000 |
| Total debt | $40.0M | $53.3M | $60.0M | $60.6M | $41.6M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | RIGL | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -18.6% | -5.5% | 3rd lowest of 20 |
| 6-month return | +52.3% | -18.1% | 2nd highest of 20 |
| Distance from 52-week high | -24.6% | -43.3% | 5th highest of 20 |
| Revenue growth (TTM) | +3.3% | +5.9% | 7th lowest of 19 |
| Operating margin | 31.4% | 11.0% | 4th highest of 18 |
| Forward P/E | 11.9× | 17.8× | 5th cheapest of 12 |
| Growth the price implies (Req g, 7 yrs) | -1.1% | 1.9% | 5th least demanding of 11 |
| Growth delivered (Del g) | +22.1% | +10.4% | 2nd highest of 11 |
| Hurdle (Req g minus delivered) | -23.2 pp | -0.9 pp | 3rd least demanding of 11 |
| ROIC minus cost of capital | +7.7 pp | +1.3 pp | 4th highest of 17 |
| EV / EBITDA | 7.6× | 4.5× | 4th most expensive of 9 |
| Net debt / EBITDA | -0.6× | -0.8× | 5th least indebted of 9 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Rigel Pharmaceuticals RIGL | United States | $741M | +52% | +3% | 31% | 11.9× | -1.1% | +22.1% |
| Jiangsu Aidea Pharmaceutical 688488.SS | China | $743M | -32% | +7% | 8% | 123.9× | 33.8% | +19.8% |
| HPGC Renmintongtai Pharmaceutical 600829.SS | China | $753M | -11% | +4% | 2% | n/a | 4.9% | +5.3% |
| Cullinan Therapeutics CGEM | United States | $728M | -22% | n/a | n/a | n/a | n/a | n/a |
| Ironwood Pharmaceuticals IRWD | United States | $725M | +4% | +26% | 61% | 3.3× | n/a | n/a |
| Arbutus Biopharma ABUS | United States | $724M | -16% | +1,079% | 81% | n/a | n/a | n/a |
| Ardelyx ARDX | United States | $724M | -58% | +18% | -8% | 225.1× | n/a | n/a |
| Hangzhou Bio-Sincerity Pharma-Tech 301096.SZ | China | $716M | -24% | +5% | -30% | 64.3× | n/a | n/a |
| China Traditional Chinese Medicine 0570.HK | Hong Kong | $771M | -29% | -16% | 0% | n/a | n/a | n/a |
| Yabao Pharmaceutical 600351.SS | China | $711M | -3% | -3% | 16% | n/a | -7.5% | -2.8% |
| Hainan Haiyao 000566.SZ | China | $710M | -19% | -18% | -50% | n/a | n/a | n/a |
| DongKook Pharmaceutical 086450.KS | South Korea | $776M | -1% | +13% | 10% | 12.4× | -6.3% | +10.6% |
| Youcare Pharmaceutical 688658.SS | China | $776M | -41% | -7% | -13% | 28.8× | n/a | n/a |
| Jiangsu Jibeier Pharmaceutical 688566.SS | China | $777M | -8% | +9% | 24% | 11.9× | 11.5% | +11.3% |
| HeiLongJiang ZBD Pharmaceutical 603567.SS | China | $705M | -29% | -82% | n/a | 6.3× | 10.5% | -25.1% |
| Bambusa Therapeutics BBTX | United States | $783M | n/a | n/a | n/a | n/a | n/a | n/a |
| Bliss GVS Pharma BLISSGVS.NS | India | $698M | +126% | +21% | 15% | n/a | 37.0% | +10.1% |
| Zhuzhou Qianjin Pharmaceutical 600479.SS | China | $787M | -3% | +4% | 11% | n/a | -1.4% | 0.0% |
| Collegium Pharmaceutical COLL | United States | $788M | -36% | +14% | 20% | 3.4× | -7.0% | +20.3% |
| Hunan Jiudian Pharmaceutical 300705.SZ | China | $789M | -18% | -5% | 13% | 17.8× | -1.1% | +26.1% |
| Philogen PHIL.MI | Italy | $694M | -7% | +295% | 79% | 32.5× | n/a | n/a |